Abstract
Emerging evidence suggests that pharmacogenetic (PGx) information can assist with identifying individuals at greatest risk for poor response or adverse drug reactions to commonly prescribed psychotropic medications (particularly antidepressants and antipsychotics). In the Pharmacogenetic-Guided Prescribing for Kids (PGx-SParK) project, we are studying the implementation of PGx testing in Alberta, Canada using a low-cost customized genetic panel run at a publicly funded provincial laboratory and offered at no cost to the patient.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Paper Title
Journal
Date
